Thông tin thuốc gốc
Chỉ định và Liều dùng
Breast cancer
Adult: 60-100 mg/m2 by infusion over 1 hr once every 3 wk. In combination w/ doxorubicin or capecitabine or as adjuvant therapy w/ doxorubicin and cyclophosphamide: 75 mg/m2 once every 3 wk. In combination w/ trastuzumab: 100 mg/m2 once every 3 wk.

Gastric adenocarcinoma, Head and neck cancer, Non-small cell lung cancer, Prostate cancer
Adult: 75 mg/m2 by infusion over 1 hr once every 3 wk. For gastric adenocarcinoma: Dose is given before cisplatin and fluorouracil. For head and neck cancer: Given before cisplatin and fluorouracil for 3 cycles followed by chemoradiotherapy or 4 wk followed by radiotherapy alone. For prostate cancer: May be given w/ oral prednisolone 5 mg bid continuously during treatment.
Suy gan
Breast cancer: Mild to moderate: Reduce dose from 100 mg/m2 to 75 mg/m2. Severe: Avoid use.
Non-small cell lung cancer; Gastric adenocarcinoma; Head and neck cancer; Prostate cancer Severe: Avoid use.
Hướng dẫn pha thuốc
Add 1 mL of diluent to a 20 mg vial to provide a soln containing 20 mg/0.8 mL or 4 mL of diluent to 80 mg vial to provide a soln containing 24 mg/mL of the drug. Shake well to ensure complete dissolution of the drug. The required amount of reconstituted soln should be injected into a 250-mL infusion bag or bottle containing NaCl 0.9% inj or dextrose 5% inj to produce a final soln of 0.3-0.74 mg/mL. For doses >200 mg, the vol of IV soln should be increased accordingly so that the concentration does not exceed 0.74 mg/mL.
Tương kỵ
Y-site: Amphotericin B, doxorubicin liposome, methylprednisolone Na succinate, nalbuphine.
Chống chỉ định
Baseline neutrophil count of <1,500 cells/mm3. Severe hepatic impairment.
Thận trọng
Patient w/ severe fluid retention, resp disorders, eye disorders. Renal and mild to moderate hepatic impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Fluid retention, localised erythema of extremities, severe neurosensory symptoms, cystoid macular oedema, severe asthenia,, infections, anaemia, thrombocytopenia, neuropathy, dysgeusia, constipation, anorexia, nail disorders, pain, nausea, diarrhoea, vomiting, mucositis, alopecia, skin reactions, myalgia; resp disorders (e.g. dyspnoea, acute pulmonary oedema, acute resp distress syndrome/pneumonitis, interstitial lung disease, interstitial pneumonia, pulmonary fibrosis), acute myeloid leukemia, renal failure.
Potentially Fatal: Toxic deaths, hepatotoxicity, neutropenia, severe hypersensitivity reactions (e.g. anaphylaxis), resp failure, tumour lysis syndrome, heart failure (when given w/ other cytotoxic drugs esp trastuzumab).
Thông tin tư vấn bệnh nhân
May cause symptoms of alcohol intoxication. May impair ability to drive or operate machinery.
Chỉ số theo dõi
Monitor haematologic, hepatic and renal functions; monitor for hypersensitivity reactions, neurosensory symptoms, GI toxicity, cutaneous reactions, visual impairment, fluid retention, epiphora, and canalicular stenosis; baseline cardiac assessment and cardiac function monitoring in patients given docetaxel w/ other cytotoxic drugs esp trastuzumab.
Quá liều
Symptoms: Bone marrow suppression, peripheral neurotoxicity and mucositis. Management: Symptomatic treatment. Admin therapeutic granulocyte-colony stimulating factor (G-CSF) as soon as possible.
Tương tác
CYP3A4 inducers, inhibitors, or substrates may alter docetaxel metabolism.
Tác dụng
Description: Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerisation of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.
Distribution: Rapidly distributed to body tissues. Plasma protein binding: >95%.
Metabolism: Extensively hepatic, by CYP3A4 isoenzyme.
Excretion: Mainly via faeces (as metabolites); via urine (approx 6%). Terminal elimination half-life: Approx 11 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Docetaxel, CID=148124, (accessed on Jan. 21, 2020)

Bảo quản
Store between 2-25°C.
Phân loại MIMS
Hóa trị gây độc tế bào
Tài liệu tham khảo
Anon. Docetaxel . Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/11/2014.

Buckingham R (ed). Docetaxel. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/11/2014.

Docetaxel Anhydrous Injection, Solution (Hospira, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/11/2014.

Docetaxel: Drug Safety Communication. U.S. FDA. Accessed 05/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Docetaxel. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 05/11/2014.

Taxotere Injection Concentrate. U.S. FDA. Accessed 05/11/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Docetaxel từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Bestdocel
  • Daxotel
  • Docetere
  • Doxekal
  • Esolat
  • Newtaxell
  • Tadocel
  • Taxotere
  • Terexol
  • Zenotere
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in